Overview

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2024-07-31

Target enrollment:

Participant gender:

Summary

There is no muture method to treat EGFR 20 insertion mutation non-small-cell lung cancer (NSCLC). the he purpose of this study is to study osimertinib combined with bevacizumab in the management of it.

Phase:

Phase 2

Details

Lead Sponsor:

Qingdao Central Hospital

Treatments:

Osimertinib